News
2 Beaten-Down Dividend Stocks With Yields Above 5% to Buy Now and Hold at Least a Decade
The benchmark S&P 500 index is up an exciting 25.8% over the past year, but many of its components haven't participated in the gains. Nvidia and other members of the "Magnificent Seven" have been
2 Stocks Down More Than 30% to Buy Right Now
The S&P 500 is soaring as this bull market roars on, but some stocks, even those that have rebounded in recent times, still are trading at much lower levels than in the past. In fact, two stocks
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer's (NYSE: PFE) gene-therapy candidate to treat Duchenne muscular dystrophy
Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
EQS-News: Newron Pharmaceuticals reports on its 2024 Investor Day in New York City
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?
It's obvious why Pfizer (NYSE: PFE) is eager to produce a medicine like Wegovy, Novo Nordisk's (NYSE: NVO) smash-hit obesity therapy that's essentially a slightly different version of its type 2
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
If you're looking to pump up your passive income stream, there are a handful of high-yield dividend stocks that deserve your attention. AbbVie (NYSE: ABBV), Ares Capital (NASDAQ: ARCC), and Realty
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) recently excited the medical community with clinical trial results from an experimental diabetes treatment it's developing. In a nutshell, it looks like a
EQS-News: Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
EQS-Adhoc: Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
EQS-News: Biotest's sustainability campaign GoFuture part of the new documentary 'Future Seeds'
Want an Extra $100 in Annual Dividend Income? Invest $1,320 in These 3 High-Yield Stocks
Would you like to widen the stream of passive income you can expect each year? Managing rental property is an option, but most retirees find this method less passive than they would like it to be.
3 No-Brainer Stocks to Buy for Under $100 Right Now
A low price doesn't necessarily mean low quality. That's true with lots of products and services. And it's true with stocks, too.
We asked Three Motley Fool contributors to name no-brainer
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
Investors looking for high-yield dividend stocks to buy now should turn their attention toward the healthcare sector: Three relatively reliable drugmakers are trading near their 52-week lows.
Their
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
Nearly everything is going right these days for Eli Lilly (NYSE: LLY). Sales and profits have been soaring. So has the share price, jumping more than 50% year to date after a 59% gain in 2023. Lilly
Want $1,000 in Dividend Income? Here's How Much You'd Need to Invest in AT&T to Get It
A high-yielding stock can be a valuable asset in your portfolio because it can generate a lot of recurring income. Investors can often find great dividend stocks in the telecom sector, where
10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year
The power of compounding is very real. It is a process that takes time, as dividend investing is not about year 1 dividend income, but rather about year 10+. In today's video, we will look at the
Where Will Amgen Be in 5 Years?
Amgen (NASDAQ: AMGN) is a top drugmaker whose shares have risen by more than 70% in five years, which is a bit shy of the S&P 500's 90% gain over that stretch. With some promising products in its
EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
EQS-Adhoc: Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
If You'd Invested $10,000 in AT&T Stock 20 Years Ago, Here's How Much You'd Have Today
Investing in AT&T (NYSE: T) over the past two decades has delivered mixed results for long-term investors. Let's break down what a $10,000 investment in AT&T would look like today, starting in June
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
When it comes to investing in high-yield dividend stocks in the pharmaceutical space, two prominent names often come to mind: Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY).
Both companies
EQS-News: Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
The Best Biotech Stock to Invest $1,000 in Right Now
Viking Therapeutics (NASDAQ: VKTX) is at an exciting point in its history. While it doesn't have any medicines approved for sale at the moment, it has a couple of mid-stage programs that are shaping
Better Passive Income Vehicle: AT&T vs. JPMorgan Nasdaq Equity Premium Income ETF
When it comes to generating passive income, investors have a wide range of options to choose from, including individual stocks and exchange-traded funds (ETFs). Two popular choices for